BioSpace News Archive

Parent Project Muscular Dystrophy, a nonprofit organization leading the fight to end Duchenne muscular dystrophy, and Duchenne UK announced the joint funding of a project to create a set of agreed and validated Patient Reported Outcomes for use in Europe and the US.

Agilent Technologies Inc. (NYSE: A) today announced that the National Medical Products Administration (NMPA, formerly the China Food and Drug Administration) has approved its PD-L1 IHC 22C3 pharmDx assay for use in China.

Entos Pharmaceuticals Inc. announced it has entered into a research, development and collaboration agreement with a clinical stage biopharmaceutical company focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, exhibited its TrelCor™ technology at the North American Spine Society annual meeting last week, including its newest product, Agilon™, which was recently cleared by the FDA for use in bone fusions.

GB-102, a pan-VEGF receptor inhibitor and potential twice-per-year therapy, is targeted to reduce the need for frequent IVT injections in retinal diseases, including wet AMD, DME, and RVO.

Epica International, Inc., received 510 clearance from the U.S. Food and Drug Administration to market its SeeFactorCT3™ Imaging Platform.

The Rogosin Institute announced the launch of a new Kidney Health Screening program.

APEKS-NP trial met primary endpoint of non-inferiority of cefiderocol compared to meropenem

Encompass Health Corp. announced it will report results for its third quarter ended Sept. 30, 2019, after the market closes on Oct. 28, 2019.

LifeSphere® MultiVigilance 10 features all new architecture and design, incorporating the latest in cognitive automation technology to deliver groundbreaking efficiency gains to PV teams